Positive data from Phase III study of Humira (AbbVie) in pediatric patients with Crohn's Disease
New data from the Phase III IMAgINE-1 trial of Humira (adalimumab), from AbbVie, shows that pediatric Crohn's Disease patients taking the drug experienced a significant improvement in select measures of health-related quality of life. The analyses assessed improvements in health-related quality of life (HRQOL) measures for pediatric patients aged 6 to 17 years with severe active Crohn's disease, taking Humira, who had an inadequate response, were intolerant or had contraindications to conventional therapy, as well as the work productivity of their caregivers throughout the 52-week study.
The analysis found Humira treatment was associated with significantly improved HRQOL compared to baseline (P<0.001) at weeks 12, 26 and 52. for all evaluations, the increase in total impact iii scores exceeded 10.8, which has been reported to be indicative of clinically meaningful improvement. the results are being presented at the european crohn's and colitis organisation 8th annual congress.>
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins